Trial results for a quality improvement initiative aimed at improving germline testing rates in prostate cancer patients were posted on ClinicalTrials.gov on 2026-01-16. The intervention led to 41 participants agreeing to proceed with germline testing.
Background
Prostate cancer is a common malignancy among men. Germline genetic testing plays an increasingly important role in identifying individuals with hereditary cancer syndromes, which can impact treatment selection, surveillance strategies, and family risk assessment. Improving the uptake of germline testing among at-risk patients with prostate cancer is a key area for quality improvement in clinical practice, as it can lead to more personalized care and better outcomes.
Trial design
This completed study, designated as Phase NA, enrolled 50 participants with Prostate Cancer. The trial was designed as a quality improvement initiative to enhance the rates of germline testing among men with prostate cancer through the implementation of an in-clinic educational session. The initiative aimed to assess patient agreement to proceed with germline testing, as well as changes in patient knowledge and attitudes towards germline testing.
Key results
The trial reported several key measurements from the educational intervention group:
- Of the participants approached with the educational intervention, 41 agreed to proceed with germline testing.
- Patient baseline knowledge of germline testing was a mean of 9.1 units on a scale (Full Range).
- Patient attitudes towards germline testing showed a mean of 9.2 units on a scale (Full Range).
- Following the educational intervention, patient knowledge of germline testing was a mean of 9.2 units on a scale (Full Range).
- Among those tested, 5 participants were found to have pathogenic germline mutations.
What this means
The results indicate that an in-clinic educational intervention can be effective in increasing the willingness of prostate cancer patients to undergo germline testing. The observed increase in patient knowledge of germline testing post-intervention suggests that the educational session contributed to better informed decision-making. The identification of pathogenic germline mutations in 5 participants underscores the clinical utility of such testing for personalized management and genetic counseling.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05470036, titled 'Improving Germline Testing in At-Risk Patients With Prostate Cancer', were posted on 2026-01-16 on clinicaltrials.gov.